Inmed Pharma’s Hiring Of Tiberend Highlights Biotech Focus – Yahoo Finance

The firm’s clients include notably companies from $200+ million market capitalization companies, like Galena Biopharma Inc. ( GALE ), to smaller companies like Advaxis Inc. ( ADXS ). Gregory Tiberend heads the team at Tiberend Strategic Advisors with many years of experience in both the public relations and healthcare industry. Over his career, Mr. Tiberend has counseled more than 50 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical service, diagnostics, healthcare services, and financial services, among others. Taking a Unique Approach InMed Pharmaceuticals’ hiring of Tiberend Strategic Advisors highlights its focus on the biotech side of the cannabis industry. By leveraging its proprietary Intelligent Cannabinoid Drug Design Platform, the company aims to rapidly identify promising new bioactive compounds in cannabis and create an accelerated pathway for drug development and commercialization of between three and five years. So far, the company has identified two compounds to treat glaucoma and arthritis, known as CTI-085 and CTI-091, respectively.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/inmed-pharmas-hiring-tiberend-highlights-152500127.html

Comments are closed.